Cyclacel Pharmaceuticals (CYCC) AI Stock Analysis

• Market Cap: $44.37M
• Dividend Yield: N/A
• Average Volume (3M): 298.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: -89.76%
• EPS Growth: 80.28%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -5.33
• Shares Outstanding: 207,336,400
• 10 Day Avg. Volume: 200,122
• 30 Day Avg. Volume: 298,511
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 27.19
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

Cyclacel Pharmaceuticals is struggling with significant financial instability, marked by operational inefficiencies and negative cash flows. The technical indicators reflect a persistent downtrend, and the lack of positive valuation metrics further weakens its investment appeal. The absence of earnings call data or notable corporate events leaves the outlook unchanged.

Cyclacel Pharmaceuticals Business Overview & Revenue Model

Company Description

Cyclacel Pharmaceuticals (CYCC) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company specializes in cell cycle control and DNA damage response technologies, aiming to address unmet medical needs in oncology. Cyclacel's core products involve a portfolio of oral therapies targeting various cancer types, with a focus on solid tumors and hematological malignancies.

How the Company Makes Money

Cyclacel Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company’s revenue model is centered around licensing agreements, collaborations, and strategic partnerships with other pharmaceutical companies. These agreements often include upfront payments, milestone payments, and royalties on sales of successfully developed products. Additionally, Cyclacel may receive funding from government grants and research collaborations, which support their clinical trials and research initiatives. As a clinical-stage company, significant revenue generation typically occurs post-commercialization of their drug candidates.

Cyclacel Pharmaceuticals Financial Statement Overview

Summary

Cyclacel Pharmaceuticals is experiencing major financial challenges, with declining revenue, persistent losses, and negative equity. Despite no debt burden, these issues highlight significant operational and financial risks.

Income Statement

Cyclacel Pharmaceuticals has shown a significant drop in revenue from $420,000 in 2023 to $74,000 in TTM (Trailing-Twelve-Months) 2024, indicating a major challenge in sustaining revenue growth. The gross profit margin is positive at 83.8% for TTM 2024, but the net profit margin remains negative due to substantial net losses. EBIT and EBITDA margins are also negative, reflecting ongoing operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet reveals a negative stockholders' equity of $-970,000 in TTM 2024, which is concerning as it indicates liabilities exceed assets. The total debt has been reduced to zero, but the negative equity ratio and debt-to-equity metrics highlight financial instability. Return on equity (ROE) cannot be calculated due to negative equity, underscoring the company's financial distress.

Cash Flow

Cyclacel's free cash flow growth rate is negative, worsening from previous periods, and operating cash flow remains deeply negative, reflecting cash outflows exceeding inflows. The operating cash flow to net income ratio is negative, emphasizing operational challenges. The free cash flow to net income ratio is skewed due to negative figures, indicating cash flow issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
74.00K	420.00K	0.00	0.00	0.00	0.00
	Gross Profit
62.00K	420.00K	-32.00K	-43.00K	-20.00K	-20.00K
	EBIT
-18.86M	-25.45M	-27.66M	-22.94M	-10.64M	-9.68M
	EBITDA
-15.52M	-25.42M	-27.62M	-22.69M	-10.62M	-9.66M
	Net Income Common Stockholders
-11.48M	-22.55M	-21.20M	-18.89M	-8.45M	-7.83M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
24.20M	3.38M	18.34M	36.56M	33.41M	11.88M
	Total Assets
26.78M	8.80M	27.50M	42.59M	36.80M	15.31M
	Total Debt
0.00	37.00K	106.00K	30.00K	1.06M	1.19M
	Net Debt
-24.20M	-3.34M	-18.24M	-36.53M	-32.35M	-10.69M
	Total Liabilities
9.51M	8.20M	11.99M	5.32M	3.54M	3.61M
	Stockholders Equity
17.27M	607.00K	15.51M	37.26M	33.26M	11.70M
Cash Flow		Free Cash Flow
-10.54M	-16.12M	-20.83M	-18.57M	-8.03M	-9.46M
	Operating Cash Flow
-10.54M	-16.11M	-20.83M	-18.54M	-7.93M	-9.45M
	Investing Cash Flow
-4.21M	-6.00K	-7.00K	-27.00K	-96.00K	28.00K
	Financing Cash Flow
7.21M	848.00K	3.00M	21.74M	29.50M	3.85M

Cyclacel Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYCC, the sentiment is Negative. The current price of 0.21 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.31, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 32.94 is Neutral, neither overbought nor oversold. The STOCH value of 18.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYCC.

Cyclacel Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	58 Neutral	$5.85B	254.51	12.21%	―	40.80%	100.62%
Sector *	48 Neutral	$6.27B	1.17	-48.19%	2.68%	17.28%	1.24%
AFMD	42 Neutral	$8.68M	―	-151.46%	―	-95.23%	-325.89%
ADCT	41 Neutral	$115.93M	―	123.38%	―	1.84%	43.40%
MEIP	41 Neutral	$12.86M	―	-93.69%	―	-100.00%	-292.59%
PSTV	37 Underperform	$14.08M	―	249.03%	―	18.54%	50.37%
CYCC	28 Underperform	$44.37M	―	-807.39%	―	-89.76%	80.28%

Cyclacel Pharmaceuticals Corporate Events

Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift

On March 31, 2025, Cyclacel Pharmaceuticals announced the delayed resignation of its co-principal financial officer, David Lazar, and two independent directors, Avraham Ben-Tzvi and David Natan, until the filing of the company’s annual report. Subsequently, on April 2, 2025, the company appointed two new independent directors, Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, to its board. The company also reported financial results for the fourth quarter, highlighting a strategic focus on developing plogosertib, a PLK1 inhibitor for advanced cancers, and the liquidation of its subsidiary, Cyclacel Limited, which is expected to reduce research and development expenses and increase stockholders’ equity by approximately $5 million.

Cyclacel Pharmaceuticals Announces New Leadership and Restructuring

On February 26, 2025, Cyclacel Pharmaceuticals announced a significant change in control and leadership following the completion of a Securities Purchase Agreement. Datuk Dr. Doris Wong Sing Ee acquired a controlling interest in Cyclacel, becoming the new CEO and Executive Director, while Kiu Cu Seng was appointed as the Chief Financial Officer. This transition marks a strategic shift for Cyclacel, potentially impacting its operations and market positioning. The company also experienced several board resignations and new appointments, indicating a broader restructuring effort.